• Resolution of haemolysis • Stable haemoglobin • Rise in haemoglobin Dose Refer to the current Induction Dose – Up to 2 g/kg over 1-2 days While a continuing treatment period of Ig product information therapy is not required, this condition is likely Additional dose may be requested when the patient’s haemoglobin sheet for further to involve prolonged haemolysis and Ig is seen has not improved. information. as life-saving. The Specialist Working Group advised that The aim should be to The aim should be to use the lowest dose possible that achieves the uncommonly, a second dose might be use the lowest dose appropriate clinical outcome for each patient. required, when the patient has not improved, possible that achieves and may be requested up to six weeks after Refer to the current product information sheet for further the appropriate the first dose. information on dose, administration and contraindications. clinical outcome for each patient. References (most recent update: July 2016) Danaee A, Howard J, Roberston B and Robinson S (2014) Hyperhaemolysis in a patient with HbH disease. Transitional Medicine, 24:244-5. Ontario Regional Blood Coordinating Network (2016). Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines, Version 3.0. [online]. Available at: http://transfusionontario.org/en/download/ontario-intravenous-immune-globulin-IVIg-utilization-management-guidelines-2/. Stokes IC, Downie PA, Wood EM, Bowden DK, Monagle PT and Barnes CD (2001) Hyperhaemolysis in sickle cells disease – an unusual and potentially complication. Medical Journal of Australia, 192:281-2.
• Resolution of haemolysis • Stable haemoglobin • Rise in haemoglobin Dose Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Induction Dose – Up to 2 g/kg over 1-2 days Additional dose may be requested when the patient’s haemoglobin has not improved. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information on dose, administration and contraindications. While a continuing treatment period of Ig therapy is not required, this condition is likely to involve prolonged haemolysis and Ig is seen as life-saving. The Specialist Working Group advised that uncommonly, a second dose might be required, when the patient has not improved, and may be requested up to six weeks after the first dose. References (most recent update: July 2016) Danaee A, Howard J, Roberston B and Robinson S (2014) Hyperhaemolysis in a patient with HbH disease. Transitional Medicine, 24:244-5. Ontario Regional Blood Coordinating Network (2016). Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines, Version 3.0. [online]. Available at: http://transfusionontario.org/en/download/ontario-intravenous-immune-globulin-IVIg-utilization-management-guidelines-2/. Stokes IC, Downie PA, Wood EM, Bowden DK, Monagle PT and Barnes CD (2001) Hyperhaemolysis in sickle cells disease – an unusual and potentially complication. Medical Journal of Australia, 192:281-2.
Haemolytic-transfusion-reaction-not-associated-with-red-cell-antibodies2017.docx